Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

NCT00058461 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

82

Enrollment

NIH

Sponsor class

Conditions

B-cell Childhood Acute Lymphoblastic Leukemia
Childhood Burkitt Lymphoma
Childhood Diffuse Large Cell Lymphoma
Childhood Immunoblastic Large Cell Lymphoma
L3 Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Large Cell Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Small Noncleaved Cell Lymphoma

Interventions

DRUG: ifosfamide
DRUG: etoposide
BIOLOGICAL: rituximab
DRUG: carboplatin
BIOLOGICAL: filgrastim
DRUG: methotrexate
DRUG: cytarabine
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)